

Annual Information Statement for:

**Orchard Therapeutics PLC
(the "Company")**

108 Cannon Street, London, EC4N 6EU, United Kingdom

1 Annual Statement for the Company's taxable year ending:	December 31, 2023
2 The Company's ordinary earnings per share, per day*:	\$0.0000000000
3 The Company's long-term capital gain per share, per day*:	\$0.0000000000
Of the amount noted above on line 3 as long-term capital gain, the following amount should be treated as ordinary income for investors for which IRC Section 1061 is applicable.	\$0.0000000000
4 Cash or property distributed or deemed to be distributed during the taxable year:	N/A

The Company will permit the shareholder to inspect and copy its permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that the Company's ordinary earnings and net capital gain, as defined in Treasury Regulations § 1.1293-1(a)(2), are computed in accordance with U.S. income tax principles, and verify these amounts and the shareholder's pro rata shares thereof. The Company believes Orchard Therapeutics PLC does not meet the definition of a Passive Foreign Investment Company, as defined in IRC Section 1297(a), for its 2023 tax year. This statement is intended to be informational only and shareholders should consult with their tax advisor concerning the overall tax consequences and U.S. reporting requirements as a result of their ownership of shares of the Company.

Signature _____

Title _____

Orchard Therapeutics PLC

*To determine your pro rata share for the year, multiply the per share, per day figure by the number of shares of the Company you owned by the days the shares were held during the taxable year.

Annual Information Statement for:

**Orchard Therapeutics (Switzerland) GmbH
("Orchard Switzerland")
KD Zug-Treuhand AG, Untermüli 7 6300 Zug, Switzerland**

1 Annual Statement for Orchard Switzerland's taxable year ending:	December 31, 2023
2 Orchard Switzerland's ordinary earnings per share, per day*:	\$0.0000043703
3 Orchard Switzerland's long-term capital gain per share, per day*:	\$0.0000000000
Of the amount noted above on line 3 as long-term capital gain, the following amount should be treated as ordinary income for investors for which IRC Section 1061 is applicable.	\$0.0000000000
4 Cash or property distributed or deemed to be distributed during the taxable year:	N/A

Orchard Switzerland will permit the shareholder to inspect and copy its permanent books of account, records, and such other documents as may be maintained by Orchard Switzerland that are necessary to establish that Orchard Switzerland's ordinary earnings and net capital gain, as defined in Treasury Regulations § 1.1293-1(a)(2), are computed in accordance with U.S. income tax principles, and verify these amounts and the shareholder's pro rata shares thereof. Since Orchard Therapeutics PLC, the parent company, believes it was not a Passive Foreign Investment Company ("PFIC"), as defined in IRC Section 1297(a), for its 2023 tax year, the PFIC status of Orchard Switzerland is not required to be analyzed. This statement is intended to be informational only and shareholders should consult with their tax advisor concerning the overall tax consequences and U.S. reporting requirements as a result of their indirect ownership of shares of Orchard Switzerland.

Signature _____

Title _____

Orchard Therapeutics (Switzerland) GmbH

*To determine your pro rata share for the year, multiply the per share, per day figure by the number of shares of Orchard Switzerland you owned by the days the shares were held during the taxable year.